Sonnet BioTherapeutics Holdings, Inc. financial data

Symbol
SONN on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Overlook Center, Suite 102, Princeton, NJ
State of incorporation
DE
Fiscal year end
September 30
Former names
Chanticleer Holdings, Inc. (to 3/31/2020), TULVINE SYSTEMS INC (to 3/31/2005)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 140 % +31.7%
Debt-to-equity 180 % -84.4%
Return On Assets -142 % +46.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.2M shares -86.5%
Common Stock, Shares, Outstanding 5.22M shares -86.4%
Entity Public Float 7.3M USD -67%
Common Stock, Value, Issued 522 USD -86.4%
Weighted Average Number of Shares Outstanding, Basic 5.04M shares +277%
Weighted Average Number of Shares Outstanding, Diluted 5.04M shares +277%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 129K USD -49.8%
Research and Development Expense 6.38M USD -57.7%
General and Administrative Expense 5.95M USD -22.2%
Operating Income (Loss) -12.3M USD +45.6%
Net Income (Loss) Attributable to Parent -7.99M USD +64.7%
Earnings Per Share, Basic 9.05 USD/shares +76.3%
Earnings Per Share, Diluted 9.04 USD/shares +76.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 5.13M USD -46.8%
Property, Plant and Equipment, Net 23.7K USD -35.1%
Operating Lease, Right-of-Use Asset 142K USD -32.5%
Other Assets, Noncurrent 488K USD +214%
Assets 5.8M USD -42.2%
Accounts Payable, Current 1.88M USD -37.9%
Accrued Liabilities, Current 3.32M USD +3.47%
Liabilities, Current 3.11M USD -51.9%
Operating Lease, Liability, Noncurrent 68.8K USD -54.2%
Liabilities 3.18M USD -52%
Retained Earnings (Accumulated Deficit) -115M USD -7.49%
Stockholders' Equity Attributable to Parent 2.62M USD -23.4%
Liabilities and Equity 5.8M USD -42.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.09M USD +47.7%
Net Cash Provided by (Used in) Financing Activities 3.84M USD -15.9%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 5.22M shares -86.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 747K USD
Deferred Tax Assets, Valuation Allowance 37.1M USD +18.6%
Deferred Tax Assets, Gross 37.2M USD +18.5%
Operating Lease, Liability 204K USD -20.1%
Depreciation 3.21K USD 0%
Lessee, Operating Lease, Liability, to be Paid 237K USD -25%
Operating Lease, Liability, Current 81.3K USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 95.5K USD +2%
Lessee, Operating Lease, Liability, to be Paid, Year One 93.6K USD +18.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33.4K USD -45.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 48.2K USD -49.5%
Deferred Tax Assets, Operating Loss Carryforwards 28M USD +8.27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 48.2K USD
Operating Lease, Payments 24.7K USD -3.31%
Additional Paid in Capital 117M USD +6.54%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 62.4K USD -13.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%